[HTML] sciencedirect.com

[HTML][HTML] Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in non-small cell lung cancer harboring uncommon EGFR mutations: Focus on afatinib

A Masood, RK Kancha, J Subramanian - Seminars in oncology, 2019 - Elsevier
The development of first-, second-, and third-generation epidermal growth factor receptor
(EGFR) tyrosine kinase inhibitors (TKIs) has revolutionized the treatment of patients with non …
被引用次数：89 相关文章

Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in non-small cell lung cancer harboring uncommon EGFR mutations: Focus on afatinib.

A Masood, RK Kancha, J Subramanian - Seminars in Oncology, 2019 - europepmc.org
The development of first-, second-, and third-generation epidermal growth factor receptor
(EGFR) tyrosine kinase inhibitors (TKIs) has revolutionized the treatment of patients with non …

[引用][C] Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in non-small cell lung cancer harboring uncommon EGFR mutations: Focus on afatinib

A Masood, RK Kancha, J Subramanian - Seminars in Oncology, 2019 - cir.nii.ac.jp
Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in non-small cell lung
cancer harboring uncommon EGFR mutations: Focus on afatinib | CiNii Research CiNii 国立 …

Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in non-small cell lung cancer harboring uncommon EGFR mutations: Focus on afatinib

A Masood, RK Kancha… - Seminars in …, 2019 - pubmed.ncbi.nlm.nih.gov
The development of first-, second-, and third-generation epidermal growth factor receptor
(EGFR) tyrosine kinase inhibitors (TKIs) has revolutionized the treatment of patients with non …